Gut microbiome in modulating immune checkpoint inhibitors.

Area of Science:

• Microbiome research
• Cancer immunology
• Immunotherapy

Background:

• The gut microbiome's role in human diseases, including cancer, is increasingly recognized.
• Microbial composition influences the effectiveness of cancer therapies, particularly immune checkpoint inhibitors (ICIs).
• Variations in gut microbiota contribute to diverse patient responses to immunotherapy.

Purpose of the Study:

• To review the intricate interactions between the microbiome, host immunity, and cancer.
• To explore strategies for modulating the gut microbiome to improve immunotherapy efficacy.
• To highlight the clinical translation potential of microbiome-targeted cancer treatments.

Main Methods:

• Literature review of preclinical models and patient cohorts.
• Analysis of studies investigating microbiome-host immunity-cancer axis.
• Synthesis of current knowledge on microbiome modulation strategies.

Main Results:

• Gut microbes are critical determinants of response to immune checkpoint inhibitors (ICIs).
• Inter-individual differences in gut microbiota explain heterogeneity in immunotherapy outcomes.
• Microbiome modulation presents a viable approach to enhance immunotherapy.

Conclusions:

• Understanding the microbiome's role in immunity and cancer is crucial for precision medicine.
• Targeting the gut microbiome can potentially expand the efficacy of cancer immunotherapies.
• Further research and clinical translation of microbiome-based strategies are warranted.